SG Americas Securities LLC Lowers Holdings in BeiGene, Ltd. (NASDAQ:BGNE)

SG Americas Securities LLC trimmed its position in BeiGene, Ltd. (NASDAQ:BGNE) by 19.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 698 shares of the company’s stock after selling 168 shares during the period. SG Americas Securities LLC’s holdings in BeiGene were worth $126,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Baillie Gifford & Co. grew its position in BeiGene by 17.9% in the 3rd quarter. Baillie Gifford & Co. now owns 3,871,598 shares of the company’s stock valued at $696,384,000 after buying an additional 588,294 shares during the last quarter. BlackRock Inc. grew its position in BeiGene by 3.8% in the 1st quarter. BlackRock Inc. now owns 2,699,444 shares of the company’s stock valued at $509,114,000 after buying an additional 98,316 shares during the last quarter. FMR LLC grew its position in BeiGene by 3.0% in the 3rd quarter. FMR LLC now owns 2,352,730 shares of the company’s stock valued at $423,186,000 after buying an additional 69,297 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in BeiGene by 68.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 775,857 shares of the company’s stock valued at $167,222,000 after buying an additional 314,764 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in BeiGene by 10.9% in the second quarter. Legal & General Group Plc now owns 284,661 shares of the company’s stock valued at $46,072,000 after acquiring an additional 27,945 shares during the period. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at BeiGene

In other BeiGene news, CFO Julia Aijun Wang sold 397 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other BeiGene news, CEO John Oyler sold 26,716 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total value of $3,977,745.24. Following the transaction, the chief executive officer now directly owns 12,084 shares in the company, valued at approximately $1,799,186.76. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Julia Aijun Wang sold 397 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $167.08, for a total transaction of $66,330.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 64,781 shares of company stock worth $10,222,381. Corporate insiders own 7.40% of the company’s stock.

BeiGene Price Performance

BeiGene stock opened at $131.86 on Thursday. BeiGene, Ltd. has a 52 week low of $131.28 and a 52 week high of $270.57. The company has a quick ratio of 2.09, a current ratio of 2.32 and a debt-to-equity ratio of 0.06. The firm’s 50-day simple moving average is $155.97 and its 200 day simple moving average is $169.12. The firm has a market capitalization of $12.61 billion, a PE ratio of -15.51 and a beta of 0.61.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings data on Monday, February 26th. The company reported ($3.53) EPS for the quarter, topping the consensus estimate of ($3.61) by $0.08. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The business had revenue of $634.40 million for the quarter, compared to analyst estimates of $632.52 million. During the same period in the previous year, the firm earned ($4.29) EPS. The business’s revenue for the quarter was up 66.9% compared to the same quarter last year. On average, equities research analysts predict that BeiGene, Ltd. will post -8.87 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Bank of America decreased their target price on shares of BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research report on Monday, April 8th. JPMorgan Chase & Co. boosted their target price on shares of BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. Guggenheim decreased their target price on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Finally, Sanford C. Bernstein decreased their target price on shares of BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a research report on Wednesday, March 27th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $251.70.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.